Back to News
Market Impact: 0.1
Avenzo Therapeutics Announces Oral Presentation of Phase 1 Data for VBC103 (AVZO-103), a Potentially Differentiated Nectin-4/TROP2 Bispecific Antibody-Drug Conjugate, by Partner VelaVigo at ESMO Asia Congress 2026
Source: Business Wire
Healthcare & Biotech
Avenzo Therapeutics announced that VelaVigo will give an oral presentation of Phase 1 data for VBC103 (AVZO-103), a potential Nectin-4/TROP2 bispecific antibody-drug conjugate. The headline provides no trial results, numerical data, or market reaction.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
More News
- J&J's 6% slide on an imperfect quarter is a gift to prospective buyers
- UnitedHealth Group tops estimates, hikes profit outlook as insurer manages high medical costs
- J&J beats earnings estimates; Middle East conflict weighs on medical-device sales
- Rhythm Pharmaceuticals launches IMCIVREE in Japan for obesity
- Liquidia (NASDAQ:LQDA) CMO Rajeev Saggar disposes of $262,528 in stock
- Alaunos completes Velaris acquisition, raises $350 million
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- AlphaSense vs Hebbia vs AllMind: Choose by Workflow
- AllMind Discusses Ontario's AI Economy with Minister Stephen Crawford and Supply Ontario CEO James Wallace